Healthline Aerosol Medicine provides this list of
references on the above named topic as a convenience to respiratory
therapists, pulmonologists and medical aerosol scientists. You
may view or print the list or use "cut/copy/paste"
commands to insert into documents. Great for students and
researchers! Disclaimer: Please note that this list is not
guaranteed to be either exhaustive or completely up-to-date.
We encourage anyone who would like to update this list, or share their special list of
references on any legitimate aerosol medicine, respiratory therapy
or related subject to forward it to Healthline Aerosol Medicine by e-mail
for posting at this web site.
Nebulized
Pentamidine
Montgomery
AB
, Luce TM, Turner J, et al.
Aerosolized pentamadine as sole therapy for Pneumocystis
carinii pneumonia in patients with acquired
immunodeficiency syndrome.
Lancet 1987;2:480-483.
Smaldone GC. Drug
delivery via aerosol systems: Concept of “aerosol
inhaled.” J
Aerosol Med 1991;4:229-235.
Montgomery AB, Debs
RJ, Luce JM, et al. Selective delivery of pentamidine to the
lung by aerosol. Am Rev Respir Dis. 1988;137:477-8.
Smaldone GC, Fuhrer J, Steigbigel RT, McPeck M. Factors
determining pulmonary deposition of aerosolized pentamidine in
patients with human immunodeficiency virus infection. American
Review of Respiratory Disease 143:727-737, 1991.
O'Riordan TG, Smaldone
GC. Exposure of health care workers to aerosolized pentamidine.
Chest. 1992;101:1494-9.
Smaldone GC, Vinciguerra C, Morra L. Urine pentamidine as an
indicator of lung pentamidine in patients receiving aerosol
therapy. Chest. 1991;100:1219-23.
Vinviguerra C, Smaldone G. Treatment time and patient
tolerance for pentamidine delivery by Respirgard II and
AeroTech II. Respir Care. 1990;35:1037-41.
Kacmarek RM. Ribavirin and pentamidine aerosols: Caregiver
beware! [editorial]. Respir Care. 1990;35:1034-6.
Kacmarek
RM.
Care-giver protection from
exposure to aerosolized pharmacologic agents. Is it necessary?
Chest. 1991;100:1104-5.
Rau JL J; Airway pharmacology. In: Scanlan CL, Wilkins RL,
Stoller JK, Eds. Egan's Fundamentals of Respiratory Care.
7 ed.
St. Louis
: Mosby; 1999.
Castro M. Treatment and
prophylaxis of Pneumocystis carinii pneumonia. Semin Respir
Infect. 1998;13:296-303.
Fishman JA. Prevention of
infection due to Pneumocystis carinii. Antimicrob Agents
Chemother. 1998;42:995-1004.
Lawrence
TE, Millecchia LL, Fedan JS.
Fluticasone propionate and pentamidine isethionate reduce
airway hyperreactivity, pulmonary eosinophilia and pulmonary
dendritic cell response in a guinea pig model of asthma. J
Pharmacol Exp Ther. 1998;284:222-7.
Turner BJ, Markson L,
Cocroft J, et al. Clinic HIV-focused features and prevention
of Pneumocystis carinii pneumonia. J Gen Intern Med.
1998;
13:16
-23.
Wei CC, Pack LL, Chan CK.
Effects of long-term aerosol pentamidine for Pneumocystis
carinii prophylaxis on pulmonary function. Chest.
1998;114:742-7.
Bucher HC, Griffith L,
Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments
against Pneumocystis carinii pneumonia and toxoplasma
encephalitis in HIV-infected patients. J Acquir Immune
Defic Syndr Hum Retrovirol. 1997;15:104-14.
Deresinski SC. Treatment of
Pneumocystis carinii pneumonia in adults with AIDS. Semin
Respir Infect. 1997;12:79-97.
Girgis I, Gualberti J,
Langan L, et al. A prospective study of the effect of I.V.
pentamidine therapy on ventricular arrhythmias and QTc
prolongation in HIV-infected patients. Chest.
1997;112:646-53.
Gupta M, Stephenson K, Gauar
S, Frenkel L. Intravenous pentamidine as an alternate for
Pneumocystis carinii pneumonia prophylaxis in children with
HIV infection. Pediatr Pulmonol Suppl. 1997;16:199-200.
Morris-Jones
SD
, Easterbrook PJ. Current
issues in the treatment and prophylaxis of Pneumocystis
carinii pneumonia in HIV infection. J Antimicrob Chemother.
1997;40:315-8.
Tabet SR, Krone MR, Hooton
TM, et al. Bacterial infections in adult patients hospitalized
with AIDS: case- control study of prophylactic efficacy of
trimethoprim- sulfamethoxazole versus aerosolized pentamidine.
Int J STD AIDS. 1997;8:563-9.
Chan M, Lee-Pack LR, Favell
K, Chan CK. Acute pulmonary effects of three nebulizers for
admin
istering aerosol pentamidine: comparison of Parineb to Fisoneb and
Respirgard II. J Aerosol Med. 1996;9:521-6.
Ewig S. The effect of
prophylaxis on the outcome of HIV-associated Pneumocystis
carinii pneumonia [letter; comment]. Chest.
1996;109:586-7.
Ewig S, Schafer H, Rockstroh
JK, et al. Effect of long-term primary aerosolized pentamidine
prophylaxis on breakthrough Pneumocystis carinii pneumonia. Eur
Respir J. 1996;9:1006-12.
Hughes WT. Recent advances
in the prevention of pneumocystis carinii pneumonia. Adv
Pediatr Infect Dis. 1996;11:163-86.
Korraa H, Saadeh C. Options
in the management of pneumonia caused by Pneumocystis carinii
in patients with acquired immune deficiency syndrome and
intolerance to trimethoprim/sulfamethoxazole. South Med J.
1996;89:272-7.
McIvor RA, Berger P, Pack
LL, et al. An effectiveness community-based clinical trial of
Respirgard II and Fisoneb nebulizers for Pneumocystis carinii
prophylaxis with aerosol pentamidine in HIV-infected
individuals.
Toronto
Aerosol Pentamidine Study
(TAPS) Group. Chest. 1996;110:141-6.
Principi N, Marchisio P,
Onorato J, et al. Long-term
admin
istration of aerosolized
pentamidine as primary prophylaxis against Pneumocystis
carinii pneumonia in infants and children with symptomatic
human immunodeficiency virus infection. J Acquir Immune
Defic Syndr Hum Retrovirol. 1996;12:158-63.
Rizzardi GP, Lazzarin A,
Musicco M, et al. Risks and benefits of aerosolized
pentamidine and cotrimoxazole in primary prophylaxis of
Pneumocystis carinii pneumonia in HIV-1- infected patients: a
two-year Italian multicentric randomized controlled trial. J
Infect. 1996;32:123-31.
Ros JJ, Langen MC, Stallen
PC, Lenderink AW. Pentamidine aerosols and environmental
contamination: health-care workers at risk. Pharm World Sci.
1996;18:148-52.
Saukkonen K, Garland R,
Koziel H. Aerosolized pentamidine as alternative primary
prophylaxis against Pneumocystis carinii pneumonia in adult
hepatic and renal transplant recipients. Chest.
1996;109:1250-5.
Yeung KT, Chan M, Chan CK.
The safety of i.v. pentamidine
admin
istered in an ambulatory
setting. Chest. 1996;110:136-40.
Balmes JR,
Estacio PL
, Quinlan P, et al. Respiratory
effects of occupational exposure to aerosolized pentamidine. J
Occup Environ Med. 1995;37:145-50.
Conte JE Jr, Golden JA.
Intrapulmonary and systemic pharmacokinetics of aerosolized
pentamidine used for prophylaxis of pneumocystis carinii
pneumonia in patients infected with the human immunodeficiency
virus. J Clin Pharmacol. 1995;35:1166-73.
Dorrell L,
McCallum
AK
, Snow MH, Ong EL. Dapsone/pyrimethamine
versus aerosolized pentamidine as prophylaxis against PCP in
HIV infection. AIDS Patient Care. 1995;9:224-8.
Kim CS, Garcia L, Wanner A.
Actual pentamidine dose delivered by Respigard II nebulizer. Eur
Respir J. 1995;8:2178-81.
Rizzardi GP, Lazzarin A,
Musicco M, et al. Better efficacy of twice-monthly than
monthly aerosolised pentamidine for secondary prophylaxis of
Pneumocystis carinii pneumonia in patients with AIDS. J
Infect. 1995;31:99-105.
Salmon-Ceron D, Fontbonne A,
Saba J, et al. Lower survival in AIDS patients receiving
dapsone compared with aerosolized pentamidine for secondary
prophylaxis of Pneumocystis carinii pneumonia. J Infect
Dis. 1995;172:656-64.
Simonds RJ, Hughes WT,
Feinberg J, Navin TR. Preventing Pneumocystis carinii
pneumonia in persons infected with human immunodeficiency
virus. Clin Infect Dis. 1995;21 Suppl 1:S44-8.
IV pentamidine prophylaxis
for PCP [news]. AIDS Patient Care. 1995;
9:42
.
Ferretti PP, Versari A, Gafa
SI, et al. Pulmonary deposition of aerosolised pentamidine
using a new nebuliser: efficiency measurements in vitro and in
vivo. Eur J Nucl Med. 1994;21:399-406.
Olree K, Stein-Gocken J.
Torsade de pointes and elevated magnesium and calcium
requirements associated with intravenous pentamidine. Nutr
Clin Pract. 1994;9:191-5.
Diot P, Le Pape A, Becquemin
MH, et al. Direct isotopic assessment of aerosolized
pentamidine deposition: influence of nebuliser. Eur J Med.
1993;2:484-8.
McSharry RJ, Kirsch CM,
Jensen
WA
, Kagawa FT. Prophylaxis of
aerosolized pentamidine-induced bronchospasm: a symptom-based
approach. Am J Med Sci. 1993;306:20-2.
Centers for Disease Control.
Recommendations for prophylaxis against Pneumocystis carinii
pneumonia for adults and adolescents infected with human
immunodeficiency virus. MMWR Morb Mortal Wkly Rep.
1992;41:1-11.
Bjornson DC, Oster CN,
Cortese LM, Nelson BA. Aerosolized pentamidine and
Pneumocystis carinii pneumonia: patient compliance and
outcomes. Ann Pharmacother. 1992;26:1066-70.
Carr A, Tindall B, Penny R,
Cooper DA. Trimethoprim-sulphamethoxazole appears more
effective than aerosolized pentamidine as secondary
prophylaxis against Pneumocystis carinii pneumonia in patients
with AIDS. AIDS. 1992;6:165-71.
Centers for Disease Control.
Recommendations for prophylaxis against Pneumocystis carinii
pneumonia for adults and adolescents infected with HIV. JAMA.
1992;267:2294-6, 2298-9.
Emergency Care Research
Institute. Pediatric PCP guidelines. Tech Respir Ther.
1992;12:4.
Emergency Care Research
Institute. Update: pentamidine booths. Tech Respir Ther.
1992;13:1-2.
Engrav
MB
, Coodley G, Magnusson AR.
Torsade de pointes after inhaled pentamidine. Ann Emerg
Med. 1992;21:1403-5.
Fahy JV, Chin DP, Schnapp
LM, et al. Effect of aerosolized pentamidine prophylaxis on
the clinical severity and diagnosis of Pneumocystis carinii
pneumonia. Am Rev Respir Dis. 1992;146:844-8.
Hardy WD, Feinberg J,
Finkelstein DM, et al. A controlled trial of
trimethoprim-sulfamethoxazole or aerosolized pentamidine for
secondary prophylaxis of Pneumocystis carinii pneumonia in
patients with the acquired immunodeficiency syndrome. N
Engl J Med. 1992;327:1842-8.
Katzman M, Meade W, Iglar K,
et al. High incidence of bronchospasm with regular
admin
istration of aerosolized pentamidine. Chest. 1992;101:79-81.
McDiarmid MA, Schaefer J,
Richard CL, et al. Efficacy of engineering controls in
reducing occupational exposure to aerosolized pentamidine. Chest.
1992;102:1764-6.
Renzi PM, Corbeil C, Chasse
M, Braidy J, Matar N. Bilateral pneumothoraces hasten
mortality in AIDS patients receiving secondary prophylaxis
with aerosolized pentamidine. Association with a lower Dco
prior to receiving aerosolized pentamidine. Chest.
1992;102:491-6.
Sattler FR, Feinberg J. New
developments in the treatment of Pneumocystis carinii
pneumonia. Chest. 1992;101:451-7.
Schneider MM, Hoepelman AI,
Eeftinck-Schattenkerk JK, et al. A controlled trial of
aerosolized pentamidine or trimethoprim- sulfamethoxazole as
primary prophylaxis against Pneumocystis carinii pneumonia in
patients with human immunodeficiency virus infection. N
Engl J Med. 1992;327:1836-41.
Smaldone GC, Dickinson G,
Marcial E, et al. Deposition of aerosolized pentamidine and
failure of pneumocystis prophylaxis. Chest.
1992;101:82-7.
Smith D, Erskine D, Steele
J, Hills D, Gazzard B. Comparison of nebuliser efficiency for
aerosolizing pentamidine. J Pharm Pharmacol.
1992;44:7-9.
Smith
DE
, Hills DA, Gazzard BG. Patient
tolerance of nebulized pentamidine or cotrimoxazole as
secondary prophylaxis for Pneumocystis carinii pneumonia
[letter]. AIDS. 1992;6:1044-5.
CDC releases recommendations
for prophylaxis against Pneumocystis carinii pneumonia. Am
Fam Physician. 1992;46:284-6.
Castellano
AR
, Nettleman MD. Cost and
benefit of secondary prophylaxis for Pneumocystis carinii
pneumonia. JAMA. 1991;266:820-4.
Centers for Disease Control.
Guidelines for prophylaxis against Pneumocystis carinii
pneumonia for children infected with human immunodeficiency
virus. JAMA. 1991;265:1637-40, 1643-4.
Dore MF, Brechot JM,
Orvoen-Frija E, et al. Acute pulmonary effects of aerosolized
pentamidine [letter; comment]. Chest. 1991;100:1177.
Emergency Care Research
Institute. Update: exposure to aerosol pentamidine. Tech
Respir Ther. 1991;11:1-4.
Fallat RJ, Kandal K. Aerosol
exhaust: escape of aerosolized medication into the patient and
caregiver's environment. Respir Care. 1991;36:1008-16.
Graham NM, Zeger SL, Park
LP, et al. Effect of zidovudine and Pneumocystis carinii
pneumonia prophylaxis on progression of HIV-1 infection to
AIDS. The Multicenter AIDS Cohort Study. Lancet.
1991;338:265-9.
Hirschel B, Lazzarin A,
Chopard P, et al. A controlled study of inhaled pentamidine
for primary prevention of Pneumocystis carinii pneumonia. N
Engl J Med. 1991;324:1079-83.
Ilowite JS, Baskin MI,
Sheetz MS, Abd AG. Delivered dose and regional distribution of
aerosolized pentamidine using different delivery systems. Chest.
1991;99:1139-44.
Leigh TR, Wiggins J, Gazzard
B, Collins JV. A comparison of several agents with two
delivery systems for the prevention of airway narrowing
induced by nebulised pentamidine isethionate. Respir Med.
1991;85:527-31.
Levine SJ, Masur H, Gill VJ,
et al. Effect of aerosolized pentamidine prophylaxis on the
diagnosis of Pneumocystis carinii pneumonia by induced sputum
examination in patients infected with the human
immunodeficiency virus. Am Rev Respir Dis.
1991;144:760-4.
Matthys H, Herceg R. Dosing
strategies for aerosol delivery to the lung parenchyma, with
specific recommendations for pentamidine. Respir Care.
1991;36:989-93.
Metersky ML, Catanzaro A.
Diagnostic approach to Pneumocystis carinii pneumonia in the
setting of prophylactic aerosolized pentamidine. Chest.
1991;100:1345-9.
Montaner JS, Lawson LM,
Gervais A, et al. Aerosol pentamidine for secondary
prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A
randomized, placebo-controlled study. Ann Intern Med.
1991;114:948-53.
Murphy RL, Lavelle JP, Allan
JD, et al. Aerosol pentamidine prophylaxis following
Pneumocystis carinii pneumonia in AIDS patients: results of a
blinded dose-comparison study using an ultrasonic nebulizer. Am
J Med. 1991;90:418-26.
Quieffin J, Hunter J,
Schechter
MT
, et al. Aerosol pentamidine-induced
bronchoconstriction. Predictive factors and preventive
therapy. Chest. 1991;100:624-7.
Shanley DJ, Luyckx BA,
Haggerty MF, Murphy TF. Spontaneous pneumothorax in AIDS
patients with recurrent Pneumocystis carinii pneumonia despite
aerosolized pentamidine prophylaxis. Chest.
1991;99:502-4.
Shelton MJ, Minor JR.
Occupational exposure to aerosolized pentamidine isethionate. Am
J Hosp Pharm. 1991;48:557-8.
Smith
DE
, Hills DA, Harman C, et al.
Nebulized pentamidine for the prevention of Pneumocystis
carinii pneumonia in AIDS patients: experience of 173 patients
and a review of the literature. Q J Med.
1991;80:619-29.
Thomas SH, O'Doherty MJ,
Page CJ, et al. Which apparatus for inhaled pentamidine? A
comparison of pulmonary deposition via eight nebulisers. Eur
Respir J. 1991;4:616-22.
Waskin H. Toxicology of
antimicrobial aerosols: A review of aerosolized ribavirin and
pentamidine. Respir Care. 1991;36:1026-36.
Baskin MI, Abd AG, Ilowite
JS. Regional deposition of aerosolized pentamidine. Effects of
body position and breathing pattern. Ann Intern Med.
1990;113:677-83.
Burnett RJ, Reents SB.
Severe hypomagnesemia induced by pentamidine. DICP.
1990;24:239-40.
Choy FN, Wilson DC, Willcox
GS,
Crocker
KS
. Experience with home
aerosolized pentamidine treatment in patients with AIDS. DICP.
1990;24:592-4.
Conte JE Jr, Chernoff D,
Feigal DW Jr, et al. Intravenous or inhaled pentamidine for
treating Pneumocystis carinii pneumonia in AIDS. A randomized
trial. Ann Intern Med. 1990;113:203-9.
Debs R, Brunette E, Fuchs H,
et al. Biodistribution, tissue reaction, and lung retention of
pentamidine aerosolized as three different salts. Am Rev
Respir Dis. 1990;142:1164-7.
Green ST
, Nathwani D, Christie PR, et
al. Domiciliary nebulized pentamidine for secondary
prophylaxis against Pneumocystis carinii pneumonia. J R Soc
Med. 1990;83:18-9.
Jensen BN, Nielsen TL,
Lerche B, et al. Prevention of Pneumocystis carinii pneumonia
relapse by aerosolised pentamidine, 60 mg biweekly, using an
Acorn System 22 nebuliser. Scand J Infect Dis.
1990;22:533-6.
Jules-Elysee KM,
Stover
DE
, Zaman MB, et al. Aerosolized
pentamidine: effect on diagnosis and presentation of
Pneumocystis carinii pneumonia. Ann Intern Med.
1990;112:750-7.
Leoung GS, Feigal DW Jr,
Montgomery AB, et al. Aerosolized pentamidine for prophylaxis
against Pneumocystis carinii pneumonia. The San Francisco
community prophylaxis trial. N Engl J Med.
1990;323:769-75.
Monk JP, Benfield P. Inhaled
pentamidine. An overview of its pharmacological properties and
a review of its therapeutic use in Pneumocystis carinii
pneumonia. Drugs. 1990;39:741-56.
Montgomery
AB
, Corkery KJ, Brunette ER, et
al. Occupational exposure to aerosolized pentamidine. Chest.
1990;98:386-8.
Murphy RL,
Noskin
GA
, Ehrenpreis ED. Acute
pancreatitis associated with aerosolized pentamidine. Am J
Med. 1990;88:53N-56N.
Nathwani D,
Green ST
, Gourlay YJ, Kennedy DH.
Aerosolised pentamidine (AP) prophylaxis for pneumocystis
carinii pneumonia (PCP) using a low cost jet nebulising system
[letter]. Scand J Infect Dis. 1990;22:379.
Newman SP,
Simonds
AK
. Aerosol therapy in AIDS. Lung.
1990;168 Suppl:685-91.
Newsome GS, Ward DJ, Pierce
PF. Spontaneous pneumothorax in patients with acquired
immunodeficiency syndrome treated with prophylactic
aerosolized pentamidine. Arch Intern Med.
1990;150:2167-8.
O'Doherty MJ, Thomas SH,
Page CJ, et al. Does inhalation of pentamidine in the supine
position increase deposition in the upper part of the lung? Chest.
1990;97:1343-8.
On A. Aerosolized
pentamidine in Pneumocystis carinii pneumonia.
Conn
Med.
1990;54:140-1.
Scannell KA. Pneumothoraces
and Pneumocystis carinii pneumonia in two AIDS patients
receiving aerosolized pentamidine. Chest.
1990;97:479-80.
Simonds
AK
, Newman SP, Johnson MA, et al.
Alveolar targeting of aerosol pentamidine. Toward a rational
delivery system. Am Rev Respir Dis. 1990;141:827-9.
Soo Hoo GW, Mohsenifar Z,
Meyer RD. Inhaled or intravenous pentamidine therapy for
Pneumocystis carinii pneumonia in AIDS. A randomized trial. Ann
Intern Med. 1990;113:195-202.
Thomas S, O'Doherty M,
Bateman N. Pneumocystis carinii pneumonia. BMJ.
1990;300:211-2.
Toronto
Aerosolized Pentamidine Study
(TAPS) Group. Acute pulmonary effects of aerosolized
pentamidine. A randomized controlled study. Chest.
1990;98:907-10.
Diagnostic and therapeutic
technology assessment. Prophylactic treatment for
opportunistic infections in HIV-positive patients: aerosolized
pentamidine. JAMA. 1990;263:2510-4.
Davey RT Jr, Margolis D,
Kleiner D, et al. Digital necrosis and disseminated
Pneumocystis carinii infection after aerosolized pentamidine
prophylaxis. Ann Intern Med. 1989;111:681-2.
Emergency Care Research
Institute. Occupational exposure to pentamidine. Tech
Respir Ther. 1989;10:4.
Girard PM, Clair B, Certain
A, et al. Comparison of plasma concentrations of aerosolized
pentamidine in nonventilated and ventilated patients with
pneumocystosis. Am Rev Respir Dis. 1989;140:1607-10.
Girard PM, Landman R,
Gaudebout C, et al. Prevention of Pneumocystis carinii
pneumonia relapse by pentamidine aerosol in zidovudine-treated
AIDS patients. Lancet. 1989;1:1348-53.
Herer B, Chinet T, Labrune
S, et al. Pancreatitis associated with pentamidine by aerosol.
BMJ. 1989;298:605.
Katzin L. AIDS file. Aerosol
pentamidine approved for patients at high PCP risk [news]. Am
J Nurs. 1989;89:463.
Miller RF, Delany S, Semple
SJ. Acute renal failure after nebulised pentamidine [letter]. Lancet.
1989;1:1271-2.
Miller RF, Godfrey Faussett
P, Semple SJ. Nebulised pentamidine as treatment for
Pneumocystis carinii pneumonia in the acquired
immunodeficiency syndrome. Thorax. 1989;44:565-9.
Montgomery AB. Prophylaxis
of Pneumocystis carinii pneumonia in patients infected with
the human immunodeficiency virus type 1. Semin Respir
Infect. 1989;4:311-7.
Montgomery
AB
, Debs RJ, Luce JM, et al.
Aerosolized pentamidine as second line therapy in patients
with AIDS and Pneumocystis carinii pneumonia. Chest.
1989;95:747-50.
O'Doherty MJ, Thomas SH,
Nunan TO, Bateman NT. Aerosolised pentamidine [letter]. Lancet.
1989;1:501-2.
Simonds AK, Newman SP,
Johnson MA, et al. Simple nebuliser modification to enhance
alveolar deposition of pentamidine. Lancet. 1989;2:953.
Simonds
AK
, Newman SP, Johnson MA, et al.
Aerosolised pentamidine [letter]. Lancet. 1989;1:221-2.
Young FE, Nightingale SL,
Cooper EC, Trapnell CB. Aerosolized pentamidine. Approved for
HIV-infected individuals at high risk for Pneumocystis carinii
pneumonia. Arch Intern Med. 1989;149:2412-3.
How to
admin
ister aerosolized pentamidine for PCP prophylaxis. AIDS Alert.
1989;
4:40
-1.
Aerosolized pentamidine: the
latest on the current controversy. AIDS Patient Care.
1989;3:6-11.
Aerosolized pentamidine and
disseminated infection with Pneumocystis carinii [letter]. Ann
Intern Med. 1989;111:442-3.
Armstrong D, Bernard E.
Aerosol pentamidine. Ann Intern Med. 1988;109:852-4.
Corkery KJ, Luce JM,
Montgomery AB. Aerosolized pentamidine for treatment and
prophylaxis of Pneumocystis carinii pneumonia: An update. Respir
Care. 1988;33:676-85.
Girard PM, Couderc LJ,
Farinotti R, et al. Ultrasonic nebulised pentamidine for
pneumocystis pneumonia [letter]. Lancet. 1988;1:1165.
Leen CL, Mandal BK. Rash due
to nebulised pentamidine [letter]. Lancet.
1988;2:1250-1.
O'Doherty MJ, Thomas S, Page
C, et al. Differences in relative efficiency of nebulisers for
pentamidine
admin
istration. Lancet. 1988;2:1283-6.
Salamone FR, Cunha BA.
Update on pentamidine for the treatment of Pneumocystis
carinii pneumonia. Clin Pharm. 1988;7:501-10.
Smith
DE
, Herd D, Gazzard BG.
Reversible bronchoconstriction with nebulised pentamidine
[letter]. Lancet. 1988;2:905.
Wordell CJ, Hauptman SP.
Treatment of Pneumocystis carinii pneumonia in patients with
AIDS. Clin Pharm. 1988;7:514-27.
Kuriyama S, Panosian C.
Respiratory pharmacology. Antibiotics. II. Aminoglycosides,
polymyxins, vancomycin, trimethoprim-sulfamethoxazole, and
pentamidine. Clin Chest Med. 1986;7:413-23.
Company
| Contacts | Products
| Sales
|
